<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006955</article-id><article-id pub-id-type="pmc">PMC11860666</article-id><article-id pub-id-type="doi">10.3390/v17020200</article-id><article-id pub-id-type="publisher-id">viruses-17-00200</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of Chimera AMP&#x02013;Endolysin with Wider Spectra Against Gram-Negative Bacteria Using High-Throughput Assay</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kogawa</surname><given-names>Masato</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-6494-6755</contrib-id><name><surname>Yoda</surname><given-names>Takuya</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsuhashi</surname><given-names>Ayumi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Matsushita</surname><given-names>Ai</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Otsuka</surname><given-names>Yoshiki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Shibagaki</surname><given-names>Shohei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7070-4690</contrib-id><name><surname>Hosokawa</surname><given-names>Masahito</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref><xref rid="af2-viruses-17-00200" ref-type="aff">2</xref><xref rid="af3-viruses-17-00200" ref-type="aff">3</xref><xref rid="af4-viruses-17-00200" ref-type="aff">4</xref><xref rid="af5-viruses-17-00200" ref-type="aff">5</xref><xref rid="c1-viruses-17-00200" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1424-5266</contrib-id><name><surname>Tsuda</surname><given-names>Soichiro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-viruses-17-00200" ref-type="aff">1</xref><xref rid="c1-viruses-17-00200" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Skurnik</surname><given-names>Mikael</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-00200"><label>1</label>bitBiome, Inc., 513 Wasedatsurumaki-Cho, Shinjuku-Ku 162-0041, Tokyo, Japan</aff><aff id="af2-viruses-17-00200"><label>2</label>Graduate School of Advanced Science and Engineering, Waseda University, 2-2 Wakamatsu-Cho, Shinjuku-Ku 162-8480, Tokyo, Japan</aff><aff id="af3-viruses-17-00200"><label>3</label>Computational Bio Big-Data Open Innovation Laboratory, National Institute of Advanced Industrial Science and Technology, 3-4-1 Okubo, Shinjuku-Ku 169-8555, Tokyo, Japan</aff><aff id="af4-viruses-17-00200"><label>4</label>Institute for Advanced Research of Biosystem Dynamics, Waseda Research Institute for Science and Engineering, 3-4-1 Okubo, Shinjuku-Ku 169-8555, Tokyo, Japan</aff><aff id="af5-viruses-17-00200"><label>5</label>Research Organization for Nano and Life Innovation, Waseda University, 513 Wasedatsurumaki-Cho, Shinjuku-Ku 162-0041, Tokyo, Japan</aff><author-notes><corresp id="c1-viruses-17-00200"><label>*</label>Correspondence: <email>masahito.hosokawa@bitbiome.co.jp</email> (M.H.); <email>soichiro.tsuda@bitbiome.co.jp</email> (S.T.)</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>200</elocation-id><history><date date-type="received"><day>27</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>25</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Bacteriophage-derived endolysins are being developed as an alternative to antimicrobials. The development of endolysins against Gram-negative bacteria requires the discovery of effective endolysins against the target species and the capability to penetrate the outer membrane of bacteria by endolysin. Here, we propose an efficient endolysin development approach that combines a data-driven endolysin search utilizing bacterial genomes with high-throughput laboratory assays. As a proof of concept, we analyzed endolysin genes detected in 273 bacterial genomes of <italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Pseudomonas</italic>, and <italic toggle="yes">Escherichia</italic>. Firstly, we conducted assays of 192 recombinants of endolysin genes obtained through in silico search from bacterial genomes and identified natural endolysins degrading peptidoglycan of <italic toggle="yes">Acinetobacter baumannii</italic>. Then, we performed high-throughput screening against Gram-negative bacteria for hundreds of chimera AMP&#x02013;endolysins, natural endolysin conjugated with antimicrobial peptide. As a result, we obtained four chimera AMP&#x02013;endolysins against A. baumannii, which demonstrated the minimum inhibitory concentration ranging from 4 to 8 &#x003bc;g/mL. Moreover, we assessed the antimicrobial spectra of these chimera AMP&#x02013;endolysins, validating that two endolysins exhibited antimicrobial efficacy against <italic toggle="yes">Pseudomonas aeruginosa</italic> and <italic toggle="yes">Escherichia coli</italic> with &#x0003c;32 &#x003bc;g/mL of concentration. This endolysin development approach can be applied to other Gram-negative bacterial targets and is expected to facilitate the acquisition of effective novel endolysins.</p></abstract><kwd-group><kwd>endolysin</kwd><kwd>gram-negative bacteria</kwd><kwd>high-throughput screening</kwd></kwd-group><funding-group><award-group><funding-source>JST FOREST JPMJFR210F</funding-source></award-group><funding-statement>This research was funded by JST FOREST JPMJFR210F (M.H.).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-00200"><title>1. Introduction</title><p>In the past few decades, antibiotics have been widely used for the treatment of bacterial infections. However, in recent years, the emergence of drug-resistant bacteria has become a global healthcare threat [<xref rid="B1-viruses-17-00200" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-00200" ref-type="bibr">2</xref>]. In particular, there are limited treatments against multidrug-resistant bacteria known as ESKAPE pathogens (<italic toggle="yes">Enterococcus faecium</italic>, <italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Acinetobacter baumannii</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Enterobacter</italic> species) which often cause severe infections. Thus, there is an urgent need for new approaches to treat drug-resistant bacteria [<xref rid="B3-viruses-17-00200" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-00200" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-00200" ref-type="bibr">5</xref>].</p><p>Endolysins, which are peptidoglycan hydrolases derived from bacteriophages, are considered promising alternatives to antibiotics. Endolysins degrade the cell walls of host bacteria from within and facilitate phage release during the lytic cycle [<xref rid="B6-viruses-17-00200" ref-type="bibr">6</xref>,<xref rid="B7-viruses-17-00200" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-00200" ref-type="bibr">8</xref>]. Endolysins typically consist of one or more cell wall-binding domains and enzymatic activity domains responsible for peptidoglycan degradation [<xref rid="B9-viruses-17-00200" ref-type="bibr">9</xref>,<xref rid="B10-viruses-17-00200" ref-type="bibr">10</xref>]. Due to the substrate selectivity of both domains, each endolysin exhibits distinct antimicrobial activity against specific bacterial species, making them potential candidates for highly selective antimicrobial agents. Many studies have been reported on obtaining endolysins mainly from isolated phage against host bacteria from 50 years ago, and the number of studies continues to grow [<xref rid="B11-viruses-17-00200" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-00200" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-00200" ref-type="bibr">13</xref>]. Moreover, several reports have highlighted the development of chimera AMP&#x02013;endolysins with altered antimicrobial spectra and increased activity through protein engineering techniques such as domain shuffling [<xref rid="B14-viruses-17-00200" ref-type="bibr">14</xref>,<xref rid="B15-viruses-17-00200" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-00200" ref-type="bibr">16</xref>,<xref rid="B17-viruses-17-00200" ref-type="bibr">17</xref>].</p><p>When using endolysins as antimicrobial agents, they need to reach the bacterial cell wall from the outside, unlike their original action inside the host cell in phage lytic cycles [<xref rid="B18-viruses-17-00200" ref-type="bibr">18</xref>] Gram-positive bacteria can be rapidly lysed upon endolysin administration because their peptidoglycan layer is located at the outermost layer of bacterial membrane. In contrast, the lytic activity of endolysins against Gram-negative bacteria is significantly reduced because their peptidoglycan layer is covered by lipopolysaccharides (the outer membrane). The ability of endolysins to penetrate the outer membrane of gram-negative bacteria is important to exhibit antimicrobial activity [<xref rid="B19-viruses-17-00200" ref-type="bibr">19</xref>]. Therefore, artificial endolysins like artilysin have been developed by conjugating charged amino acid residues like antimicrobial peptides (AMPs) to the end of the endolysins [<xref rid="B20-viruses-17-00200" ref-type="bibr">20</xref>,<xref rid="B21-viruses-17-00200" ref-type="bibr">21</xref>,<xref rid="B22-viruses-17-00200" ref-type="bibr">22</xref>,<xref rid="B23-viruses-17-00200" ref-type="bibr">23</xref>]. This enhances their antimicrobial ability by improving their outer membrane-penetrating ability. Because cationic peptides destabilizing the outer membrane exhibit a lower species specificity and the peptidoglycans of Gram-negative bacteria are less diverse than those of Gram-negative bacteria, artilysins targeting Gram-negative bacteria tend to have broader antimicrobial spectra compared to those targeting Gram-positive bacteria [<xref rid="B24-viruses-17-00200" ref-type="bibr">24</xref>].</p><p>In this study, we aimed to develop multiple endolysins against Gram-negative bacteria, using a data-driven approach to design engineered endolysins with different antimicrobial spectra. We applied a high-throughput screening method to evaluate the resulting endolysins. Firstly, we conducted assays of 192 recombinants of endolysin genes obtained through an in silico search from bacterial genomes, determining natural endolysins against <italic toggle="yes">A. baumannii</italic>. Subsequently, we performed assays of 744 recombinants of chimera AMP&#x02013;endolysins, which were created by random conjugation of the natural endolysins and AMPs. As a result, we obtained four chimera AMP&#x02013;endolysins against <italic toggle="yes">A. baumannii</italic>. Furthermore, we evaluated the antimicrobial spectra of these chimera AMP&#x02013;endolysins, confirming that some endolysins exhibited antimicrobial activity against <italic toggle="yes">P. aeruginosa</italic> and <italic toggle="yes">E. coli</italic>, indicating broad antimicrobial spectra. Our approach holds the potential for the efficient development of endolysins with different characteristics depending on their intended applications.</p></sec><sec id="sec2-viruses-17-00200"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-17-00200"><title>2.1. Bacterial Strains, Media, and Growth Conditions</title><p>The bacterial strains used in this study were as follows (<xref rid="app1-viruses-17-00200" ref-type="app">Table S4</xref>): <italic toggle="yes">Acinetobacter baumannii</italic> str. NBRC 110489 (National Institute of Technology and Evaluation, NITE), <italic toggle="yes">Pseudomonas aeruginosa</italic> str. NBRC 12582 (NITE), <italic toggle="yes">Escherichia coli</italic> str. ATCC 10798, <italic toggle="yes">Bacillus subtilis</italic> str. ATCC 6633, <italic toggle="yes">Enterobacter cloacae</italic> str. NBRC 13535 (NITE), <italic toggle="yes">Enterococcus faecalis</italic> str. NBRC 100482 (NITE), <italic toggle="yes">Fusobacterium nucleatum</italic> str. JCM 8532 (JCM), <italic toggle="yes">Klebsiella aerogenes</italic> str. NBRC 13534 (NITE), <italic toggle="yes">Klebsiella pneumoniae</italic> str. BAA-1705 (ATCC), <italic toggle="yes">Staphylococcus aureus</italic> str. NBRC 100910 (NITE), and <italic toggle="yes">Streptococcus gallolyticus</italic> str. ATCC BAA-2069 (BEI resources). The following media were used for the culture of the bacterial strains: LB broth, Miller (Nacalai Tesque, kyoto Japan) for <italic toggle="yes">A. baumannii</italic>, <italic toggle="yes">E. coli</italic> and <italic toggle="yes">P. aeruginosa</italic>, brain heart infusion medium (Sigma-Aldrich, St. Louis, MO, USA) for <italic toggle="yes">B. subtilis</italic> and <italic toggle="yes">F. nucleatum</italic>, Lactobacilli MRS broth (BD) for <italic toggle="yes">E. faecalis</italic>, NBRC medium 802 (hipolypepton 10 g, yeast extract 2 g, MgSO<sub>4</sub>&#x000b7;7H<sub>2</sub>O 1 g in 1 L distilled water) for <italic toggle="yes">E. cloacae</italic> and <italic toggle="yes">K. aerogenes</italic>, tryptic soy broth (TSB) (Becton Dickinson, Franklin Lakes, NJ, USA) for <italic toggle="yes">K. pneumoniae</italic> and <italic toggle="yes">S. gallolyticus</italic>, and TSB with 7.5% NaCl (Nacalai Tesque, Japan) for <italic toggle="yes">S. aureus</italic>. <italic toggle="yes">B. subtilis</italic> was incubated at 30 &#x000b0;C, and the other strains were incubated at 37 &#x000b0;C. The AnaeroPack System (Mitsubishi Gas Chemical, Tokyo, Japan) was used for <italic toggle="yes">F. nucleatum</italic>.</p></sec><sec id="sec2dot2-viruses-17-00200"><title>2.2. DNA Extraction and Genome Sequencing</title><p>Genomic sequences of <italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Pseudomonas</italic>, and <italic toggle="yes">Escherichia</italic> from bacterial isolate or single bacterial cells were collected to use for in silico search of endolysins. To acquire bacterial isolate genomic sequences, DNAs of the 96 isolates of <italic toggle="yes">Acinetobacter</italic> bacterium and 96 isolates of <italic toggle="yes">Pseudomonas</italic> bacterium were extracted using the DNeasy 96 Blood &#x00026; Tissue kit (Qiagen, Hilden, Germany). Sequencing libraries were prepared using the QIAseq FX DNA Library Kit (Qiagen, Japan). Each library was sequenced using the Illumina NextSeq2000 2 &#x000d7; 150 bp configuration (Illumina, San Diego, CA, USA). In addition to the genomic data of the isolates, single-cell genomic data obtained in previous research were also used in the endolysin search [<xref rid="B25-viruses-17-00200" ref-type="bibr">25</xref>]. Finally, 273 genomes were collected (116 <italic toggle="yes">Acinetobacter</italic> genomes, 144 <italic toggle="yes">Pseudomonas</italic> genomes, 13 <italic toggle="yes">Escherichia</italic> genomes).</p></sec><sec id="sec2dot3-viruses-17-00200"><title>2.3. Identification of Endolysin Genes from Microbial Genome Data</title><p>Endolysin genes were searched from the collected bacterial genomic sequences by the same in silico pipeline as in our previous studies [<xref rid="B26-viruses-17-00200" ref-type="bibr">26</xref>]. Prophage sequences in bacterial genomes were predicted by PhageBoost 0.1.7 (options: -cs 200) [<xref rid="B27-viruses-17-00200" ref-type="bibr">27</xref>]. Then, genes on the prophage regions were called by PHANOTATE 1.5.0 [<xref rid="B28-viruses-17-00200" ref-type="bibr">28</xref>], and endolysin-like genes were collected by DIAMOND 2.0.5 search using endolysin genes in the RefSeq database [<xref rid="B29-viruses-17-00200" ref-type="bibr">29</xref>]. Finally, Pfam domains on the collected genes were predicted by InterProScan 5.54-87 (options: -appl Pfam) [<xref rid="B30-viruses-17-00200" ref-type="bibr">30</xref>], and endolysin candidates were selected based on the presence of the known endolysin-associated domains [<xref rid="B31-viruses-17-00200" ref-type="bibr">31</xref>]. Unless otherwise noted, bioinformatic tools were conducted with the default option.</p></sec><sec id="sec2dot4-viruses-17-00200"><title>2.4. Construction of the Endolysin Library</title><p>Endolysin gene fragments were acquired by PCR from the extracted genomic DNA of bacterial isolates or single-cell MDA (multiple displacement amplification) products, which is the same way as in previous studies [<xref rid="B32-viruses-17-00200" ref-type="bibr">32</xref>]. PCR amplicons were purified with the Wizard SV Gel and PCR Clean-Up System kit (Promega, Japan). Then, PCR amplicons and linearized pET17b vectors were assembled with NEBuilder HiFi DNA Assembly (NEB, Japan). The endolysin libraries were transformed into competent <italic toggle="yes">E. coli</italic> BL21(DE3)pLysS (Promega, Madison, WI, USA) by heat shock, and the recombinants were selected on LB agar plates containing 100 &#x003bc;g/mL ampicillin and 20 &#x003bc;g/mL chloramphenicol. In the construction of a chimeric endolysin library, PCR products of antimicrobial peptide genes and endolysin genes, which can be ligated by the linker sequence as N&#x02032;-[AMP]-GAGAGA-[Endolysin]-His6-C&#x02032;, were assembled into pET17b vector.</p></sec><sec id="sec2dot5-viruses-17-00200"><title>2.5. Endolysin Expression and Lysate Preparation</title><p>Single colonies of recombinants were picked into each well of 96-well deep plate filled with 500 &#x000b5;L of LB medium containing 100 &#x003bc;g/mL ampicillin and 20 &#x003bc;g/mL chloramphenicol. After incubation for 16 h at 37 &#x000b0;C, the 25 &#x000b5;L of culture was transferred into 500 &#x000b5;L of LB medium supplemented with the Overnight Express Autoinduction System 1 (Novagen, Japan). Then, cultures of recombinants were continuously incubated for 5 h at 37 &#x000b0;C and 16 h at 16 &#x000b0;C with shaking at 1000 rpm. After the centrifugation at 2000&#x000d7; <italic toggle="yes">g</italic> for 20 min, the cell pellets were treated with chloroform vapor for 1 h at room temperature to lyse the cells. Then, the residual chloroform was removed by incubation of the plate at 37 &#x000b0;C for 30 min. Finally, the pellets were suspended with 500 &#x000b5;L of HEPES buffer (20 mM HEPES-NaOH, 150 mM NaCl, pH 7.4) containing 0.4 U/mL DNase I (Takara, Japan) and incubated for 1 h at 30 &#x000b0;C. The lysate was stored at 4 &#x000b0;C.</p></sec><sec id="sec2dot6-viruses-17-00200"><title>2.6. Plate Lysis Assay</title><p>Plate lysis assays were performed with a modified method from a previous study [<xref rid="B33-viruses-17-00200" ref-type="bibr">33</xref>]. Cultures of <italic toggle="yes">A. baumannii</italic> and <italic toggle="yes">P. aeruginosa</italic> in 100 mL media were autoclaved, and sterilized cells were collected by centrifugation. The cell pellets were suspended in three ml of HEPES buffer. Then, the peptidoglycan agar plate was made from a mixture of the cell suspension and 100 mL of HEPES buffer containing 1.5 % agarose. Four &#x000b5;L of lysate of recombinants was dropped onto the plate and lysis was observed by transparent area after incubation for 1 h at 37 &#x000b0;C. The transparent area was measured using ImageJ with the following commands: &#x0201c;Subtract Background&#x0201d; -&#x0003e; &#x0201c;Auto Local Threshold&#x0201d; with MidGrey method -&#x0003e; &#x0201c;Fill Holes&#x0201d; -&#x0003e; &#x0201c;Analyze Particles&#x0201d; [<xref rid="B34-viruses-17-00200" ref-type="bibr">34</xref>].</p></sec><sec id="sec2dot7-viruses-17-00200"><title>2.7. Growth Inhibition Assay</title><p><italic toggle="yes">A. baumannii</italic> were cultured overnight and diluted to OD<sub>600</sub> = 0.1 with 2&#x000d7; BD BBL Mueller Hinton II Broth (BD) with 100 mM NaCl. The diluted cell suspension and the lysate of recombinants of 50 &#x000b5;L each were mixed and incubated for 16 h at 37 &#x000b0;C. Cell growth was monitored by measuring OD<sub>600</sub> by Infinite 200 PRO M Nano+ (Tecan). Then, the normalized bacterial growth was calculated according to the following equation:<disp-formula id="FD1-viruses-17-00200"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>G</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>w</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>b</mml:mi><mml:mi>l</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>The samples exhibiting &#x0003c;80% cell growth compared to the control sample (<italic toggle="yes">A. baumannii</italic> treated with lysate of the recombinant containing empty pET17b vector) were selected as growth-inhibiting endolysin.</p></sec><sec id="sec2dot8-viruses-17-00200"><title>2.8. Expression and Purification of Endolysins</title><p>The recombinants were cultured at 37 &#x000b0;C until the OD<sub>600</sub> value reached 0.4&#x02013;0.6, and IPTG was added to a final concentration of 0.5 mM. After overnight incubation at 16 &#x000b0;C, bacterial cells were harvested from 50 mL of culture and lysed with xTractor&#x02122; buffer (Clontech, Shiga, Japan) containing 2.5 U/mL DNase I (Takara Bio, Shiga, Japan) on ice. Then, endolysin protein was purified with the Capturem&#x02122; His-Tagged Purification Maxiprep Kit (Clontech, Japan) according to product protocols. After dialysis with PBS, the size of the purified protein was evaluated by SDS-PAGE with e-PAGEL (1020L, ATTO, Tokyo, Japan).</p></sec><sec id="sec2dot9-viruses-17-00200"><title>2.9. Endolysin Activity Assay</title><p>MIC values were determined using the methods based on the broth microdilution method for MIC determination, in which the CLSI guideline is M07-A9. The overnight culture of bacteria was inoculated into the appropriate growth medium and incubated at 37 &#x000b0;C until the OD<sub>600</sub> reached 0.8. The bacterial cells were collected and suspended in a doubled concentration of cation-adjusted Mueller&#x02013;Hinton broth (ca-MHB, BD) to achieve an OD<sub>600</sub> value of 0.1. The cell suspension was diluted 100-fold and exposed to endolysins or antibiotics in a series of two-fold serial dilutions in the 96-well microtiter plate. After 18 h of incubation at 37 &#x000b0;C, the turbidity of the cell suspension was measured. The MIC was defined as the lowest drug concentration that kept the OD<sub>600</sub> of cell suspension below 0.2, based on the turbidity of the suspension in which no bacterial growth was visually observed. The normalized bacterial growth was calculated according to the equation described in <xref rid="sec2dot7-viruses-17-00200" ref-type="sec">Section 2.7</xref>.</p><p>A time&#x02013;kill curve was evaluated by kinetic absorbance of the bacterial cell suspensions for short-term. The bacterial cells in the overnight culture were collected and resuspended into the reaction buffer (20 mM Tris pH 7.5, 150 mM NaCl, 0.9 mM MgCl<sub>2</sub>, 2.5 mM CaCl<sub>2</sub>). This cell suspension was adjusted to OD<sub>600</sub> = 0.8 with the reaction buffer, and 90 &#x000b5;L of cell suspension and 10 &#x000b5;L of endolysin solution at the concentration of 256 &#x003bc;g/mL were mixed. The measurement of the OD<sub>600</sub> immediately started and was recorded every minute for 30 min at room temperature. Then, the OD<sub>600</sub> at n minutes was normalized according to the following equation:<disp-formula id="FD2-viruses-17-00200"><mml:math id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>m</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mo>_</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo>_</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mrow><mml:mi>O</mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo>_</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot10-viruses-17-00200"><title>2.10. Cytotoxicity Assay</title><p>The cytotoxicity effect of endolysins was evaluated with the Caco-2 cell line. A Caco-2 cell suspension was prepared with the DMEM medium (500 mL of Advanced DMEM/F12 (Gibco, Shinagawa-ku,Japan), 100 mL of fetal bovine serum, 6 mL of penicillin&#x02013;streptomycin solution (Fujifilm, Tokyo,Japan), and 6 mL of GlutaMax (Gibco, Japan)) at a concentration of 1 &#x000d7; 10<sup>5</sup> cells/mL. The cell suspension of 100 &#x000b5;L was added to each well of the 96-well microtiter plate and incubated for 24 h at 37 &#x000b0;C in 5% CO<sub>2</sub>. After the incubation, the cells were exposed with endolysins or compounds at a concentration of 50 or 100 &#x003bc;g/mL for 24 h at 37 &#x000b0;C in 5% CO<sub>2</sub>. Then, 10 &#x000b5;L of Cell Counting Kit-8 reagent (MedChemExpress Ltd., Shibuya-ku, Japan) was added to each well. After incubation for 4 h, the OD450 was measured to evaluate cell viability.</p></sec><sec id="sec2dot11-viruses-17-00200"><title>2.11. Biofilm Assay</title><p>The biofilm formation of <italic toggle="yes">P. aeruginosa</italic> was performed using methods from a previous study [<xref rid="B35-viruses-17-00200" ref-type="bibr">35</xref>]. The overnight culture of <italic toggle="yes">P. aeruginosa</italic> was adjusted to OD600 = 0.001 with LB broth and statically incubated for 24 h at 37 &#x000b0;C in the 96-well microtiter plate. The culture was removed from the plate by decanting and the biofilm was gently washed three times with PBS. Then, an endolysin solution and an antibiotic solution were prepared with the reaction buffer (20 mM Tris pH 7.5, 150 mM NaCl, 0.9 mM MgCl<sub>2</sub>, 2.5 mM CaCl<sub>2</sub>), and the biofilm was exposed to endolysin or antibiotics at the concentration of 10 &#x003bc;g/mL for 24 h at 37 &#x000b0;C. The reaction solution was removed from the plate by decanting and the remaining biofilm was gently washed with PBS. The biofilm was stained with 0.05% crystal violet stain (20% methanol including 0.5 mg/mL crystal violet) for 15 min and washed with PBS after removal of the stain. Finally, the stained biofilm was suspended with 33% acetic acid, and OD<sub>590</sub> of the suspension was measured.</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-00200"><title>3. Results</title><sec id="sec3dot1-viruses-17-00200"><title>3.1. Identification of Endolysin Genes from Genomes of Gram-Negative Bacteria</title><p>We conducted an in silico search of endolysin genes from the genomes of <italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Pseudomonas</italic>, and <italic toggle="yes">Escherichia</italic>, which are related to drug-resistant Gram-negative bacteria (<xref rid="viruses-17-00200-f001" ref-type="fig">Figure 1</xref>A). We collected bacterial genomes (116 <italic toggle="yes">Acinetobacter</italic>, 144 <italic toggle="yes">Pseudomonas</italic>, 13 <italic toggle="yes">Escherichia</italic>) from our database containing genomic sequences of human-associated bacteria obtained through the genome analysis of isolates or single-cell genome sequencing [<xref rid="B25-viruses-17-00200" ref-type="bibr">25</xref>]. As a result of an endolysin gene search within the prophage regions of the bacterial genome, we detected 701 candidate genes (367, 315, and 19 genes from <italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Pseudomonas</italic>, and <italic toggle="yes">Escherichia</italic> bacterial genomes, respectively). Subsequently, we constructed recombinants of 52 randomly selected genes expressed in <italic toggle="yes">Escherichia coli</italic> BL21(DE3) and evaluated their ability to lyse <italic toggle="yes">A. baumannii</italic> (<xref rid="app1-viruses-17-00200" ref-type="app">Table S1</xref>). As a result of the plate lysis assay toward 192 recombinants, 18 recombinants demonstrated lytic activity, suggesting their potential antimicrobial activity against <italic toggle="yes">A. baumannii</italic> (<xref rid="viruses-17-00200-f001" ref-type="fig">Figure 1</xref>B). Among these 18 recombinants, five exhibited particularly significant lytic activity. Notably, two of these were obtained from different bacterial species and genera, <italic toggle="yes">Acinetobacter junii</italic> and <italic toggle="yes">Pseudomonas mendocina</italic>, hinting at endolysins with antimicrobial activity across a broad range of bacterial species. On the other hand, in the plate lysis assay with <italic toggle="yes">P. aeruginosa</italic>, over 95% of the recombinants displayed degradation (<xref rid="app1-viruses-17-00200" ref-type="app">Table S2</xref>). Based on these results, we decided to use all 52 endolysin genes for the next experiment, the construction of chimera AMP&#x02013;endolysins.</p></sec><sec id="sec3dot2-viruses-17-00200"><title>3.2. Screening of Chimeric Endolysin Libraries</title><p>Next, we aimed to construct chimera AMP&#x02013;endolysins capable of penetrating the outer membrane of Gram-negative bacteria by conjugating AMPs with the 52 natural endolysins (<xref rid="viruses-17-00200-f002" ref-type="fig">Figure 2</xref>A). With reference to previous studies [<xref rid="B21-viruses-17-00200" ref-type="bibr">21</xref>,<xref rid="B36-viruses-17-00200" ref-type="bibr">36</xref>,<xref rid="B37-viruses-17-00200" ref-type="bibr">37</xref>], we selected 11 cecropins, one of AMP, and conjugated them randomly with the 52 endolysins by Gibson assembly, and the gene fragments of chimera AMP&#x02013;endolysins were cloned into the expression vector. The domain structure of the chimera AMP&#x02013;endolysins was designed as N&#x02019;-[AMP]-GAGAGA-[Endolysin]-His6-C&#x02019;. Through the random assembly reaction, we constructed an expression library comprising up to 572 different chimera AMP&#x02013;endolysins.</p><p>We then evaluated the activity of chimera AMP&#x02013;endolysins against <italic toggle="yes">A. baumannii</italic>. Lysates were prepared for 744 recombinants from the expression library of chimera AMP&#x02013;endolysins, and a growth inhibitory assay against <italic toggle="yes">A. baumannii</italic> was conducted. Monitoring the growth of <italic toggle="yes">A. baumannii</italic> treated with lysates based on culture turbidity revealed 37 recombinants expected to be expressing active chimera AMP&#x02013;endolysins against <italic toggle="yes">A. baumannii</italic>. Compared to the lysate of recombinant containing empty expression vector, the lysate of the 37 recombinants decreased turbidity of the <italic toggle="yes">A. baumannii</italic> culture to less than 80%. Sanger sequencing of the 37 recombinants was performed, and 17 unique chimera AMP&#x02013;endolysins were found (<xref rid="app1-viruses-17-00200" ref-type="app">Table S3</xref>). Notably, the top five chimera AMP&#x02013;endolysins that exhibited relatively strong growth inhibition activity all shared the same AMP sequence (Q86PR4), suggesting the importance of AMP in the antimicrobial activity against Gram-negative bacteria. Eleven chimera AMP&#x02013;endolysins contained five natural endolysin genes with high lytic activity, and this indicated that not only AMPs but also endolysins contributed to growth inhibition. These results highlighted the significance of both AMP and endolysin combinations in determining the target of antimicrobial activity against Gram-negative bacteria.</p></sec><sec id="sec3dot3-viruses-17-00200"><title>3.3. Identification of Active Chimeric Endolysin Against A. baumannii</title><p>We attempted to evaluate the minimum inhibitory concentrations (MIC) of 17 chimera AMP&#x02013;endolysins against <italic toggle="yes">A. baumannii</italic>. Initially, protein expression conditions were investigated for the 17 chimera AMP&#x02013;endolysins, and purified proteins of 12 chimera AMP&#x02013;endolysins were acquired with concentrations exceeding 256 &#x003bc;g/mL, which is required for subsequent assays. Following the broth microdilution method based on the CLSI guideline M07-A9, the MIC value against <italic toggle="yes">A. baumannii</italic> was evaluated for the 12 chimera AMP&#x02013;endolysins, and four chimera AMP&#x02013;endolysins (bbgn0031, bbgn0033, bbgn0043, and bbgn0044) demonstrated MIC values ranging from 4 to 8 &#x003bc;g/mL (<xref rid="viruses-17-00200-f003" ref-type="fig">Figure 3</xref>). These MIC values were comparable to similar chimeric endolysin levels reported in previous studies [<xref rid="B38-viruses-17-00200" ref-type="bibr">38</xref>,<xref rid="B39-viruses-17-00200" ref-type="bibr">39</xref>]. Most of the remaining eight chimera AMP&#x02013;endolysins also exhibited a growth-reducing effect on <italic toggle="yes">A. baumannii</italic> under the conditions of 32 &#x003bc;g/mL addition, but growth inhibition was not observed within the tested concentration range (<xref rid="app1-viruses-17-00200" ref-type="app">Figure S1</xref>). Furthermore, a time&#x02013;kill curve assay of the four chimera AMP&#x02013;endolysins that showed growth inhibition against <italic toggle="yes">A. baumannii</italic> was also performed, and bbgn0033 exhibited the highest activity, reducing the relative turbidity compared to the control to 70% (<xref rid="app1-viruses-17-00200" ref-type="app">Figure S2</xref>).</p></sec><sec id="sec3dot4-viruses-17-00200"><title>3.4. Antibacterial Spectrum of Chimera AMP&#x02013;Endolysins</title><p>To understand the antimicrobial spectrum of the four chimera AMP&#x02013;endolysins, MIC tests against 10 additional bacterial species were performed (<xref rid="viruses-17-00200-t001" ref-type="table">Table 1</xref>). No chimera AMP&#x02013;endolysins showed growth inhibitory activity against the four Gram-positive bacteria (<italic toggle="yes">Staphylococcus aureus</italic>, <italic toggle="yes">Streptococcus gallolyticus</italic>, <italic toggle="yes">Bacillus subtilis</italic>, <italic toggle="yes">Enterococcus faecalis</italic>). When tested against six Gram-negative bacteria (<italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, <italic toggle="yes">Enterobacter cloacae</italic>, <italic toggle="yes">Klebsiella aerogenes</italic>, <italic toggle="yes">Klebsiella pneumoniae</italic>, <italic toggle="yes">Fusobacterium nucleatum</italic>), three chimera AMP&#x02013;endolysins (bbgn0031, bbgn0033, and bbgn0043) showed MIC values of 8&#x02013;16 &#x003bc;g/mL against <italic toggle="yes">P. aeruginosa</italic>. These three endolysins are composed of the same natural endolysin derived from the <italic toggle="yes">Pseudomonas</italic> genome, so their growth inhibitory activity against <italic toggle="yes">P. aeruginosa</italic> was as expected. In addition, bbgn0031 and bbgn0033 also showed MIC values of 16&#x02013;32 &#x003bc;g/mL against <italic toggle="yes">E. coli</italic>, while bbgn0043 showed no growth inhibitory activity. Both combinations, chimera AMP&#x02013;endolysins composed of the same natural endolysin and different AMPs (bbgn0031, bbgn0043) and those composed of the different natural endolysin and the same AMPs (bbgn0031, bbgn0043), showed different antimicrobial spectra, suggesting that the appropriate combination of endolysin and AMP is highly important to selective antimicrobial activity.</p></sec><sec id="sec3dot5-viruses-17-00200"><title>3.5. Cytotoxicity Assay of Chimera AMP&#x02013;Endolysins</title><p>To examine the cytotoxicity of the chimera AMP&#x02013;endolysins, a cytotoxicity assay using the Cell Counting Kit-8 was performed on the Caco-2 cell line derived from human colon cancer epithelial cells. As a result, no decrease in cell viability was observed in any of the chimeric ELs even after 24 h of treatment with a concentration of 100 &#x003bc;g/mL (<xref rid="viruses-17-00200-f004" ref-type="fig">Figure 4</xref>A), which is a much higher concentration than the MIC against <italic toggle="yes">A. baumannii</italic>.</p></sec><sec id="sec3dot6-viruses-17-00200"><title>3.6. Biofilm Degradation Assay of Chimera AMP&#x02013;Endolysins</title><p>The biofilm degradation activity of chimera AMP&#x02013;endolysins was evaluated using <italic toggle="yes">P. aeruginosa</italic>, which is known as one of the drug-resistant bacterial species that form a biofilm. The results showed that all four chimera AMP&#x02013;endolysins reduced the amount of biofilm to the same extent under the conditions in which they were added (<xref rid="viruses-17-00200-f004" ref-type="fig">Figure 4</xref>B). <italic toggle="yes">P. aeruginosa</italic> biofilm degradation was observed even in bbgn0044, which did not inhibit <italic toggle="yes">P. aeruginosa</italic> growth in the antimicrobial spectral assay.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-00200"><title>4. Discussion</title><p>In this study, we have developed chimera AMP&#x02013;endolysins with the ability to penetrate the outer membrane of Gram-negative bacteria through the conjugation of endolysins acquired through in silico exploration of Gram-negative bacterial genomes with AMPs. We applied high-throughput screening of hundreds of samples to evaluate chimeric endolysin library containing 500 types of AMP-conjugated endolysins and discovered multiple chimera AMP&#x02013;endolysins which had antimicrobial activity toward Gram-negative bacteria and different antimicrobial spectra from each other. While many recent studies still find novel endolysins from the isolated phages [<xref rid="B40-viruses-17-00200" ref-type="bibr">40</xref>,<xref rid="B41-viruses-17-00200" ref-type="bibr">41</xref>,<xref rid="B42-viruses-17-00200" ref-type="bibr">42</xref>], our approach successfully identified multiple endolysins with diverse antimicrobial spectra through in silico analysis and the screening process. This represents a significant advancement in the field, as the ability to acquire a broad range of antimicrobial candidates simultaneously accelerates the applicability of the endolysins.</p><p>Our data-driven approach was based on the comprehensive genome analysis of both isolated and uncultured bacteria. This approach enables us to search for endolysins from the genomes of closely related species of target bacteria, as demonstrated by the discovery of an <italic toggle="yes">A. junii</italic>-derived endolysin capable of lysing <italic toggle="yes">A. baumannii</italic>. However, in other words, even in data-driven approaches, information about the host bacteria that endolysins and their associated phages infect is important. In recent years, research on phage metagenomics has been increasing, and novel genetic information derived from phages is also being accumulated [<xref rid="B43-viruses-17-00200" ref-type="bibr">43</xref>]. However, linking phages to their host organisms remains a significant challenge [<xref rid="B44-viruses-17-00200" ref-type="bibr">44</xref>]. The single-cell bacterial genomics may be one of the solutions to accumulating useful phage-derived genetic information because this technology can provide the genes of phages with those of their host bacteria at the same time [<xref rid="B26-viruses-17-00200" ref-type="bibr">26</xref>]. Single-cell genomics can also provide genetic information unreached with the metagenomics method, making it a promising tool for uncovering novel sequences, such as the <italic toggle="yes">Pseudomonas</italic>-derived endolysins used in bbgn0031, bbgn0033, and bbgn0043 and showing low similarity to NCBI nr database. Additionally, although the strength of activity varied, the three chimera AMP&#x02013;endolysins commonly exhibited antimicrobial activity against similar bacterial species. This is consistent with the previous research indicating that the muralytic activity, a key determinant of the antimicrobial spectrum, is driven by the endolysins rather than the AMP [<xref rid="B45-viruses-17-00200" ref-type="bibr">45</xref>]. This further highlights the importance of accumulating novel sequences for the development of endolysins with diverse antimicrobial spectra.</p><p>Degradation of the <italic toggle="yes">P. aeruginosa</italic> biofilm was observed with bbgn0044 despite its lack of growth inhibition in antimicrobial spectral assays. This activity may be attributed to its specificity for peptidoglycans synthesized during biofilm formation, as <italic toggle="yes">P. aeruginosa</italic> alters peptidoglycan composition between the planktonic and biofilm states [<xref rid="B46-viruses-17-00200" ref-type="bibr">46</xref>]. While such specificity can limit broad-spectrum applications, precise control over the endolysin activity offers the potential for a wide range of applications by tailoring them to specific bacterial forms or conditions. With an understanding of target-specific bacterial properties, the strategic development of endolysins with defined targets can maximize their effectiveness and expand their utility across therapeutic and industrial domains.</p><p>We developed chimera AMP&#x02013;endolysins against the target Gram-negative bacteria through the conjugation of natural endolysins and AMPs and evaluated their activity with a high-throughput assay toward 744 samples in a single experiment within a week. In this study, since the theoretical maximum number of chimera AMP&#x02013;endolysins was 554, we presumed that an assay of several hundred recombinants was sufficient. However, when considering both natural endolysin genes obtained through comprehensive in silico exploration and chimeric endolysin genes obtained through domain shuffling as screening targets, further throughput improvement of the assay is required, as in the previous research [<xref rid="B45-viruses-17-00200" ref-type="bibr">45</xref>]. The development of ultra-high-throughput screening technologies, such as microfluidics-based systems, will be critical for exploring the full potential of chimeric libraries [<xref rid="B47-viruses-17-00200" ref-type="bibr">47</xref>]. Moreover, refined in silico screening utilizing recent tools like Foldseek is also important for the efficient selection of endolysin candidates [<xref rid="B48-viruses-17-00200" ref-type="bibr">48</xref>].</p><p>In conclusion, our study highlights the potential of data-driven endolysin development as a powerful approach for discovering multiple endolysins with various antimicrobial spectra. By integrating advances in genomic sequencing, bioinformatics, and screening technologies, this approach is expected to be further enhanced and contribute to the acquisition of useful endolysins.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the Human Genome Center, University of Tokyo for providing the super-computing resource. We thank the Gunma University Graduate School of Medicine for providing the isolated bacterial strains for genome sequencing.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-17-00200"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/v17020200/s1">https://www.mdpi.com/article/10.3390/v17020200/s1</uri>, Figure S1: MIC assay of chimeric endolysin candidates against <italic toggle="yes">A. baumannii,</italic> Bar plots showed relative growth of <italic toggle="yes">A. baumannii</italic> treated by chimeric endolysin (A) bbgn0030, (B) bbgn0036, (C) bbgn0038 and (D) bbgn0039 (E) bbgn0040, (F) bbgn0042, (G) bbgn0045 and (H) bbgn0046. The relative growth was calculated from the absorbance of culture. The absorbance of culture which was not treated by endolysin was used as the standard value. Significance was analyzed by the Tukey-Kramer test based on one-way ANOVA and is indicated by asterisks compared to growth of the untreated bacteria (*: <italic toggle="yes">p</italic> &#x0003c; 0.05, **: <italic toggle="yes">p</italic> &#x0003c; 0.01). The image below the graph shows a visual observation of the culture. Figure S2. Time-kill curve of chimeric endolysins against <italic toggle="yes">A. baumannii</italic>: Table S1: Tested candidate endolysins. Table S2: Result of Plate lysis assay. Table S3: Conjugated proteins of chimeric endolysins inhibiting <italic toggle="yes">A. baumannii</italic> growth. Table S4: Bacterial strains used in this study.</p><supplementary-material id="viruses-17-00200-s001" position="float" content-type="local-data"><media xlink:href="viruses-17-00200-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.T.; methodology, M.K., T.Y. and S.T.; investigation, M.K., T.Y., A.M. (Ayumi Matsuhashi), A.M. (Ai Matsushita), S.S. and Y.O.; data curation, M.K.; writing&#x02014;original draft preparation, M.K.; writing&#x02014;review and editing, M.H. and S.T.; visualization, M.K.; supervision, S.T.; project administration, S.T.; funding acquisition, M.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Amino acid sequences of chimera AMP&#x02013;endolysins are shown in <xref rid="app1-viruses-17-00200" ref-type="app">Table S3</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>M.K., T.Y., A.M. (Ayumi Matsuhashi), A.M. (Ai Matsushita), Y.O., S.S. and S.T. are employees of bitBiome, Inc. at the time of this study. M.H. holds shares in bitBiome, Inc.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-00200"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nikaido</surname><given-names>H.</given-names></name>
</person-group><article-title>Multidrug Resistance in Bacteria</article-title><source>Annu. Rev. Biochem.</source><year>2009</year><volume>78</volume><elocation-id>119</elocation-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.78.082907.145923</pub-id><pub-id pub-id-type="pmid">19231985</pub-id>
</element-citation></ref><ref id="B2-viruses-17-00200"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prestinaci</surname><given-names>F.</given-names></name>
<name><surname>Pezzotti</surname><given-names>P.</given-names></name>
<name><surname>Pantosti</surname><given-names>A.</given-names></name>
</person-group><article-title>Antimicrobial resistance: A global multifaceted phenomenon</article-title><source>Pathog. Glob. Health</source><year>2015</year><volume>109</volume><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1179/2047773215Y.0000000030</pub-id><pub-id pub-id-type="pmid">26343252</pub-id>
</element-citation></ref><ref id="B3-viruses-17-00200"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Breijyeh</surname><given-names>Z.</given-names></name>
<name><surname>Jubeh</surname><given-names>B.</given-names></name>
<name><surname>Karaman</surname><given-names>R.</given-names></name>
</person-group><article-title>Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>1340</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25061340</pub-id><pub-id pub-id-type="pmid">32187986</pub-id>
</element-citation></ref><ref id="B4-viruses-17-00200"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Oliveira</surname><given-names>D.M.P.</given-names></name>
<name><surname>Forde</surname><given-names>B.M.</given-names></name>
<name><surname>Kidd</surname><given-names>T.J.</given-names></name>
<name><surname>Harris</surname><given-names>P.N.A.</given-names></name>
<name><surname>Schembri</surname><given-names>M.A.</given-names></name>
<name><surname>Beatson</surname><given-names>S.A.</given-names></name>
<name><surname>Paterson</surname><given-names>D.L.</given-names></name>
<name><surname>Walker</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Antimicrobial Resistance in ESKAPE Pathogens</article-title><source>Clin. Microbiol. Rev.</source><year>2020</year><volume>33</volume><fpage>e00181-19</fpage><pub-id pub-id-type="doi">10.1128/CMR.00181-19</pub-id><pub-id pub-id-type="pmid">32404435</pub-id>
</element-citation></ref><ref id="B5-viruses-17-00200"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Imran</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>M.N.</given-names></name>
<name><surname>Dasgupta</surname><given-names>A.</given-names></name>
<name><surname>Rana</surname><given-names>P.</given-names></name>
<name><surname>Srinivas</surname><given-names>N.</given-names></name>
<name><surname>Chopra</surname><given-names>S.</given-names></name>
</person-group><article-title>Novel Approaches for the Treatment of Infections Due to Multidrug-Resistant Bacterial Pathogens</article-title><source>Future Med. Chem.</source><year>2022</year><volume>14</volume><fpage>1133</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.4155/fmc-2022-0029</pub-id><pub-id pub-id-type="pmid">35861021</pub-id>
</element-citation></ref><ref id="B6-viruses-17-00200"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Rubio</surname><given-names>L.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>D.</given-names></name>
<name><surname>Donovan</surname><given-names>D.M.</given-names></name>
<name><surname>Mart&#x000ed;nez</surname><given-names>B.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>P.</given-names></name>
</person-group><article-title>Phage lytic proteins: Biotechnological applications beyond clinical antimicrobials</article-title><source>Crit. Rev. Biotechnol.</source><year>2016</year><volume>36</volume><fpage>542</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.3109/07388551.2014.993587</pub-id><pub-id pub-id-type="pmid">25603721</pub-id>
</element-citation></ref><ref id="B7-viruses-17-00200"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmelcher</surname><given-names>M.</given-names></name>
<name><surname>Donovan</surname><given-names>D.M.</given-names></name>
<name><surname>Loessner</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Bacteriophage Endolysins as Novel Antimicrobials</article-title><source>Future Microbiol.</source><year>2012</year><volume>7</volume><fpage>1147</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.2217/fmb.12.97</pub-id><pub-id pub-id-type="pmid">23030422</pub-id>
</element-citation></ref><ref id="B8-viruses-17-00200"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sui</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>T.</given-names></name>
<name><surname>Zhen</surname><given-names>J.</given-names></name>
<name><surname>Ren</surname><given-names>H.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
</person-group><article-title>Design, Screening, and Characterization of Engineered Phage Endolysins with Extracellular Antibacterial Activity against Gram-Negative Bacteria</article-title><source>Appl. Environ. Microbiol.</source><year>2023</year><volume>89</volume><fpage>e00581-23</fpage><pub-id pub-id-type="doi">10.1128/aem.00581-23</pub-id><pub-id pub-id-type="pmid">37338346</pub-id>
</element-citation></ref><ref id="B9-viruses-17-00200"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmelcher</surname><given-names>M.</given-names></name>
<name><surname>Loessner</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Bacteriophage endolysins: Applications for food safety</article-title><source>Curr. Opin. Biotechnol.</source><year>2016</year><volume>37</volume><fpage>76</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2015.10.005</pub-id><pub-id pub-id-type="pmid">26707470</pub-id>
</element-citation></ref><ref id="B10-viruses-17-00200"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aslam</surname><given-names>B.</given-names></name>
<name><surname>Arshad</surname><given-names>M.I.</given-names></name>
<name><surname>Aslam</surname><given-names>M.A.</given-names></name>
<name><surname>Muzammil</surname><given-names>S.</given-names></name>
<name><surname>Siddique</surname><given-names>A.B.</given-names></name>
<name><surname>Yasmeen</surname><given-names>N.</given-names></name>
<name><surname>Khurshid</surname><given-names>M.</given-names></name>
<name><surname>Rasool</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>M.</given-names></name>
<name><surname>Rasool</surname><given-names>M.H.</given-names></name>
<etal/>
</person-group><article-title>Bacteriophage Proteome: Insights and Potentials of an Alternate to Antibiotics</article-title><source>Infect. Dis. Ther.</source><year>2021</year><volume>10</volume><fpage>1171</fpage><lpage>1193</lpage><pub-id pub-id-type="doi">10.1007/s40121-021-00446-2</pub-id><pub-id pub-id-type="pmid">34170506</pub-id>
</element-citation></ref><ref id="B11-viruses-17-00200"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdelrahman</surname><given-names>F.</given-names></name>
<name><surname>Easwaran</surname><given-names>M.</given-names></name>
<name><surname>Daramola</surname><given-names>O.I.</given-names></name>
<name><surname>Ragab</surname><given-names>S.</given-names></name>
<name><surname>Lynch</surname><given-names>S.</given-names></name>
<name><surname>Oduselu</surname><given-names>T.J.</given-names></name>
<name><surname>Khan</surname><given-names>F.M.</given-names></name>
<name><surname>Ayobami</surname><given-names>A.</given-names></name>
<name><surname>Adnan</surname><given-names>F.</given-names></name>
<name><surname>Torrents</surname><given-names>E.</given-names></name>
<etal/>
</person-group><article-title>Phage-Encoded Endolysins</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>124</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10020124</pub-id><pub-id pub-id-type="pmid">33525684</pub-id>
</element-citation></ref><ref id="B12-viruses-17-00200"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abdurahman</surname><given-names>M.A.</given-names></name>
<name><surname>Durukan</surname><given-names>&#x00130;.</given-names></name>
<name><surname>Din&#x000e7;er</surname><given-names>T.</given-names></name>
<name><surname>Pekta&#x0015f;</surname><given-names>S.</given-names></name>
<name><surname>Karata&#x0015f;</surname><given-names>E.</given-names></name>
<name><surname>Kili&#x000e7;</surname><given-names>A.O.</given-names></name>
</person-group><article-title><italic toggle="yes">Staphylococcus aureus</italic> Bacteriophage 52 Endolysin Exhibits Anti-Biofilm and Broad Antibacterial Activity Against Gram-Positive Bacteria</article-title><source>Protein J.</source><year>2023</year><volume>42</volume><fpage>596</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1007/s10930-023-10145-1</pub-id><pub-id pub-id-type="pmid">37634214</pub-id>
</element-citation></ref><ref id="B13-viruses-17-00200"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.-H.</given-names></name>
<name><surname>Lee</surname><given-names>H.</given-names></name>
<name><surname>Park</surname><given-names>M.-K.</given-names></name>
</person-group><article-title>Isolation, characterization, and application of a novel, lytic phage vB_SalA_KFSST3 with depolymerase for the control of Salmonella and its biofilm on cantaloupe under cold temperature</article-title><source>Food Res. Int.</source><year>2023</year><volume>172</volume><fpage>113062</fpage><pub-id pub-id-type="doi">10.1016/j.foodres.2023.113062</pub-id><pub-id pub-id-type="pmid">37689855</pub-id>
</element-citation></ref><ref id="B14-viruses-17-00200"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>S&#x000e3;o-Jos&#x000e9;</surname><given-names>C.</given-names></name>
</person-group><article-title>Engineering of Phage-Derived Lytic Enzymes: Improving Their Potential as Antimicrobials</article-title><source>Antibiotics</source><year>2018</year><volume>7</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics7020029</pub-id><pub-id pub-id-type="pmid">29565804</pub-id>
</element-citation></ref><ref id="B15-viruses-17-00200"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heselpoth</surname><given-names>R.D.</given-names></name>
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Moult</surname><given-names>J.</given-names></name>
<name><surname>Nelson</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Increasing the stability of the bacteriophage endolysin PlyC using rationale-based FoldX computational modeling</article-title><source>Protein Eng. Des. Sel.</source><year>2015</year><volume>28</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/protein/gzv004</pub-id><pub-id pub-id-type="pmid">25740429</pub-id>
</element-citation></ref><ref id="B16-viruses-17-00200"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Islam</surname><given-names>M.M.</given-names></name>
<name><surname>Kim</surname><given-names>D.</given-names></name>
<name><surname>Kim</surname><given-names>K.</given-names></name>
<name><surname>Park</surname><given-names>S.-J.</given-names></name>
<name><surname>Akter</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Bang</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Kim</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>J.C.</given-names></name>
<etal/>
</person-group><article-title>Engineering of lysin by fusion of antimicrobial peptide (cecropin A) enhances its antibacterial properties against multidrug-resistant <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>988522</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.988522</pub-id><pub-id pub-id-type="pmid">36225352</pub-id>
</element-citation></ref><ref id="B17-viruses-17-00200"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vander Elst</surname><given-names>N.</given-names></name>
<name><surname>Bert</surname><given-names>J.</given-names></name>
<name><surname>Favoreel</surname><given-names>H.</given-names></name>
<name><surname>Lavigne</surname><given-names>R.</given-names></name>
<name><surname>Meyer</surname><given-names>E.</given-names></name>
<name><surname>Briers</surname><given-names>Y.</given-names></name>
</person-group><article-title>Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens</article-title><source>Microb. Biotechnol.</source><year>2023</year><volume>16</volume><fpage>2367</fpage><lpage>2386</lpage><pub-id pub-id-type="doi">10.1111/1751-7915.14339</pub-id><pub-id pub-id-type="pmid">37853918</pub-id>
</element-citation></ref><ref id="B18-viruses-17-00200"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gontijo</surname><given-names>M.T.P.</given-names></name>
<name><surname>Jorge</surname><given-names>G.P.</given-names></name>
<name><surname>Brocchi</surname><given-names>M.</given-names></name>
</person-group><article-title>Current Status of Endolysin-Based Treatments against Gram-Negative Bacteria</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1143</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10101143</pub-id><pub-id pub-id-type="pmid">34680724</pub-id>
</element-citation></ref><ref id="B19-viruses-17-00200"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Love</surname><given-names>M.J.</given-names></name>
<name><surname>Abeysekera</surname><given-names>G.S.</given-names></name>
<name><surname>Muscroft-Taylor</surname><given-names>A.C.</given-names></name>
<name><surname>Billington</surname><given-names>C.</given-names></name>
<name><surname>Dobson</surname><given-names>R.C.J.</given-names></name>
</person-group><article-title>On the catalytic mechanism of bacteriophage endolysins: Opportunities for engineering</article-title><source>Biochim. Biophys. Acta BBA-Proteins Proteom.</source><year>2020</year><volume>1868</volume><elocation-id>140302</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbapap.2019.140302</pub-id></element-citation></ref><ref id="B20-viruses-17-00200"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Briers</surname><given-names>Y.</given-names></name>
<name><surname>Walmagh</surname><given-names>M.</given-names></name>
<name><surname>Grymonprez</surname><given-names>B.</given-names></name>
<name><surname>Biebl</surname><given-names>M.</given-names></name>
<name><surname>Pirnay</surname><given-names>J.-P.</given-names></name>
<name><surname>Defraine</surname><given-names>V.</given-names></name>
<name><surname>Michiels</surname><given-names>J.</given-names></name>
<name><surname>Cenens</surname><given-names>W.</given-names></name>
<name><surname>Aertsen</surname><given-names>A.</given-names></name>
<name><surname>Miller</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Art-175 Is a Highly Efficient Antibacterial against Multidrug-Resistant Strains and Persisters of Pseudomonas aeruginosa</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>3774</fpage><lpage>3784</lpage><pub-id pub-id-type="doi">10.1128/AAC.02668-14</pub-id><pub-id pub-id-type="pmid">24752267</pub-id>
</element-citation></ref><ref id="B21-viruses-17-00200"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Dai</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>C.</given-names></name>
</person-group><article-title>Design SMAP29-LysPA26 as a Highly Efficient Artilysin against Pseudomonas aeruginosa with Bactericidal and Antibiofilm Activity</article-title><source>Microbiol. Spectr.</source><year>2021</year><volume>9</volume><fpage>e00546-21</fpage><pub-id pub-id-type="doi">10.1128/Spectrum.00546-21</pub-id><pub-id pub-id-type="pmid">34878337</pub-id>
</element-citation></ref><ref id="B22-viruses-17-00200"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Zhao</surname><given-names>S.</given-names></name>
<name><surname>Dou</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Zhi</surname><given-names>Y.</given-names></name>
<name><surname>Wen</surname><given-names>L.</given-names></name>
</person-group><article-title>Engineered endolysin-based &#x0201c;artilysins&#x0201d; for controlling the gram-negative pathogen Helicobacter pylori</article-title><source>AMB Express</source><year>2021</year><volume>11</volume><fpage>63</fpage><pub-id pub-id-type="doi">10.1186/s13568-021-01222-8</pub-id><pub-id pub-id-type="pmid">33913058</pub-id>
</element-citation></ref><ref id="B23-viruses-17-00200"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gouveia</surname><given-names>A.</given-names></name>
<name><surname>Pinto</surname><given-names>D.</given-names></name>
<name><surname>Veiga</surname><given-names>H.</given-names></name>
<name><surname>Antunes</surname><given-names>W.</given-names></name>
<name><surname>Pinho</surname><given-names>M.G.</given-names></name>
<name><surname>S&#x000e3;o-Jos&#x000e9;</surname><given-names>C.</given-names></name>
</person-group><article-title>Synthetic antimicrobial peptides as enhancers of the bacteriolytic action of staphylococcal phage endolysins</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>1245</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-05361-1</pub-id><pub-id pub-id-type="pmid">35075218</pub-id>
</element-citation></ref><ref id="B24-viruses-17-00200"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schleifer</surname><given-names>K.H.</given-names></name>
<name><surname>Kandler</surname><given-names>O.</given-names></name>
</person-group><article-title>Peptidoglycan types of bacterial cell walls and their taxonomic implications</article-title><source>Bacteriol. Rev.</source><year>1972</year><volume>36</volume><fpage>407</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1128/br.36.4.407-477.1972</pub-id><pub-id pub-id-type="pmid">4568761</pub-id>
</element-citation></ref><ref id="B25-viruses-17-00200"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kogawa</surname><given-names>M.</given-names></name>
<name><surname>Nishikawa</surname><given-names>Y.</given-names></name>
<name><surname>Saeki</surname><given-names>T.</given-names></name>
<name><surname>Yoda</surname><given-names>T.</given-names></name>
<name><surname>Arikawa</surname><given-names>K.</given-names></name>
<name><surname>Takeyama</surname><given-names>H.</given-names></name>
<name><surname>Hosokawa</surname><given-names>M.</given-names></name>
</person-group><article-title>Revealing within-species diversity in uncultured human gut bacteria with single-cell long-read sequencing</article-title><source>Front. Microbiol.</source><year>2023</year><volume>14</volume><elocation-id>1133917</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2023.1133917</pub-id><pub-id pub-id-type="pmid">36910196</pub-id>
</element-citation></ref><ref id="B26-viruses-17-00200"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ide</surname><given-names>K.</given-names></name>
<name><surname>Saeki</surname><given-names>T.</given-names></name>
<name><surname>Arikawa</surname><given-names>K.</given-names></name>
<name><surname>Yoda</surname><given-names>T.</given-names></name>
<name><surname>Endoh</surname><given-names>T.</given-names></name>
<name><surname>Matsuhashi</surname><given-names>A.</given-names></name>
<name><surname>Takeyama</surname><given-names>H.</given-names></name>
<name><surname>Hosokawa</surname><given-names>M.</given-names></name>
</person-group><article-title>Exploring strain diversity of dominant human skin bacterial species using single-cell genome sequencing</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>955404</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.955404</pub-id><pub-id pub-id-type="pmid">35992707</pub-id>
</element-citation></ref><ref id="B27-viruses-17-00200"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sir&#x000e9;n</surname><given-names>K.</given-names></name>
<name><surname>Millard</surname><given-names>A.</given-names></name>
<name><surname>Petersen</surname><given-names>B.</given-names></name>
<name><surname>Gilbert</surname><given-names>M.T.P.</given-names></name>
<name><surname>Clokie</surname><given-names>M.R.J.</given-names></name>
<name><surname>Sicheritz-Pont&#x000e9;n</surname><given-names>T.</given-names></name>
</person-group><article-title>Rapid discovery of novel prophages using biological feature engineering and machine learning</article-title><source>NAR Genom. Bioinforma.</source><year>2021</year><volume>3</volume><elocation-id>lqaa109</elocation-id><pub-id pub-id-type="doi">10.1093/nargab/lqaa109</pub-id></element-citation></ref><ref id="B28-viruses-17-00200"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McNair</surname><given-names>K.</given-names></name>
<name><surname>Zhou</surname><given-names>C.</given-names></name>
<name><surname>Dinsdale</surname><given-names>E.A.</given-names></name>
<name><surname>Souza</surname><given-names>B.</given-names></name>
<name><surname>Edwards</surname><given-names>R.A.</given-names></name>
</person-group><article-title>PHANOTATE: A novel approach to gene identification in phage genomes</article-title><source>Bioinformatics</source><year>2019</year><volume>35</volume><fpage>4537</fpage><lpage>4542</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btz265</pub-id><pub-id pub-id-type="pmid">31329826</pub-id>
</element-citation></ref><ref id="B29-viruses-17-00200"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buchfink</surname><given-names>B.</given-names></name>
<name><surname>Reuter</surname><given-names>K.</given-names></name>
<name><surname>Drost</surname><given-names>H.-G.</given-names></name>
</person-group><article-title>Sensitive protein alignments at tree-of-life scale using DIAMOND</article-title><source>Nat. Methods</source><year>2021</year><volume>18</volume><fpage>366</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1038/s41592-021-01101-x</pub-id><pub-id pub-id-type="pmid">33828273</pub-id>
</element-citation></ref><ref id="B30-viruses-17-00200"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quevillon</surname><given-names>E.</given-names></name>
<name><surname>Silventoinen</surname><given-names>V.</given-names></name>
<name><surname>Pillai</surname><given-names>S.</given-names></name>
<name><surname>Harte</surname><given-names>N.</given-names></name>
<name><surname>Mulder</surname><given-names>N.</given-names></name>
<name><surname>Apweiler</surname><given-names>R.</given-names></name>
<name><surname>Lopez</surname><given-names>R.</given-names></name>
</person-group><article-title>InterProScan: Protein domains identifier</article-title><source>Nucleic Acids Res.</source><year>2005</year><volume>33</volume><fpage>W116</fpage><pub-id pub-id-type="doi">10.1093/nar/gki442</pub-id><pub-id pub-id-type="pmid">15980438</pub-id>
</element-citation></ref><ref id="B31-viruses-17-00200"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>H.</given-names></name>
<name><surname>Melo</surname><given-names>L.D.R.</given-names></name>
<name><surname>Santos</surname><given-names>S.B.</given-names></name>
<name><surname>N&#x000f3;brega</surname><given-names>F.L.</given-names></name>
<name><surname>Ferreira</surname><given-names>E.C.</given-names></name>
<name><surname>Cerca</surname><given-names>N.</given-names></name>
<name><surname>Azeredo</surname><given-names>J.</given-names></name>
<name><surname>Kluskens</surname><given-names>L.D.</given-names></name>
</person-group><article-title>Molecular Aspects and Comparative Genomics of Bacteriophage Endolysins</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>4558</fpage><lpage>4570</lpage><pub-id pub-id-type="doi">10.1128/JVI.03277-12</pub-id><pub-id pub-id-type="pmid">23408602</pub-id>
</element-citation></ref><ref id="B32-viruses-17-00200"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoda</surname><given-names>T.</given-names></name>
<name><surname>Matsuhashi</surname><given-names>A.</given-names></name>
<name><surname>Matsushita</surname><given-names>A.</given-names></name>
<name><surname>Shibagaki</surname><given-names>S.</given-names></name>
<name><surname>Sasakura</surname><given-names>Y.</given-names></name>
<name><surname>Aoki</surname><given-names>K.</given-names></name>
<name><surname>Hosokawa</surname><given-names>M.</given-names></name>
<name><surname>Tsuda</surname><given-names>S.</given-names></name>
</person-group><article-title>Uncovering novel endolysins against methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> using microbial single-cell genome sequencing</article-title><source>bioRxiv</source><year>2023</year><pub-id pub-id-type="doi">10.1101/2023.06.22.546026</pub-id></element-citation></ref><ref id="B33-viruses-17-00200"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sitthisak</surname><given-names>S.</given-names></name>
<name><surname>Manrueang</surname><given-names>S.</given-names></name>
<name><surname>Khongfak</surname><given-names>S.</given-names></name>
<name><surname>Leungtongkam</surname><given-names>U.</given-names></name>
<name><surname>Thummeepak</surname><given-names>R.</given-names></name>
<name><surname>Thanwisai</surname><given-names>A.</given-names></name>
<name><surname>Burton</surname><given-names>N.</given-names></name>
<name><surname>Dhanoa</surname><given-names>G.K.</given-names></name>
<name><surname>Tsapras</surname><given-names>P.</given-names></name>
<name><surname>Sagona</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Antibacterial activity of vB_AbaM_PhT2 phage hydrophobic amino acid fusion endolysin, combined with colistin against <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>7470</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-33822-8</pub-id><pub-id pub-id-type="pmid">37156803</pub-id>
</element-citation></ref><ref id="B34-viruses-17-00200"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>C.A.</given-names></name>
<name><surname>Rasband</surname><given-names>W.S.</given-names></name>
<name><surname>Eliceiri</surname><given-names>K.W.</given-names></name>
</person-group><article-title>NIH Image to ImageJ: 25 years of image analysis</article-title><source>Nat. Methods</source><year>2012</year><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id>
</element-citation></ref><ref id="B35-viruses-17-00200"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gajd&#x000e1;cs</surname><given-names>M.</given-names></name>
<name><surname>Bar&#x000e1;th</surname><given-names>Z.</given-names></name>
<name><surname>K&#x000e1;rp&#x000e1;ti</surname><given-names>K.</given-names></name>
<name><surname>Szab&#x000f3;</surname><given-names>D.</given-names></name>
<name><surname>Usai</surname><given-names>D.</given-names></name>
<name><surname>Zanetti</surname><given-names>S.</given-names></name>
<name><surname>Donadu</surname><given-names>M.G.</given-names></name>
</person-group><article-title>No Correlation between Biofilm Formation, Virulence Factors, and Antibiotic Resistance in Pseudomonas aeruginosa: Results from a Laboratory-Based In Vitro Study</article-title><source>Antibiotics</source><year>2021</year><volume>10</volume><elocation-id>1134</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10091134</pub-id><pub-id pub-id-type="pmid">34572716</pub-id>
</element-citation></ref><ref id="B36-viruses-17-00200"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>M.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>H.</given-names></name>
</person-group><article-title>Antibacterial Activity of a Novel Peptide-Modified Lysin Against <italic toggle="yes">Acinetobacter baumannii</italic> and Pseudomonas aeruginosa</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><elocation-id>1471</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2015.01471</pub-id><pub-id pub-id-type="pmid">26733995</pub-id>
</element-citation></ref><ref id="B37-viruses-17-00200"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jung</surname><given-names>C.-J.</given-names></name>
<name><surname>Liao</surname><given-names>Y.-D.</given-names></name>
<name><surname>Hsu</surname><given-names>C.-C.</given-names></name>
<name><surname>Huang</surname><given-names>T.-Y.</given-names></name>
<name><surname>Chuang</surname><given-names>Y.-C.</given-names></name>
<name><surname>Chen</surname><given-names>J.-W.</given-names></name>
<name><surname>Kuo</surname><given-names>Y.-M.</given-names></name>
<name><surname>Chia</surname><given-names>J.-S.</given-names></name>
</person-group><article-title>Identification of potential therapeutic antimicrobial peptides against <italic toggle="yes">Acinetobacter baumannii</italic> in a mouse model of pneumonia</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>7318</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-86844-5</pub-id><pub-id pub-id-type="pmid">33795739</pub-id>
</element-citation></ref><ref id="B38-viruses-17-00200"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peng</surname><given-names>S.-Y.</given-names></name>
<name><surname>You</surname><given-names>R.-I.</given-names></name>
<name><surname>Lai</surname><given-names>M.-J.</given-names></name>
<name><surname>Lin</surname><given-names>N.-T.</given-names></name>
<name><surname>Chen</surname><given-names>L.-K.</given-names></name>
<name><surname>Chang</surname><given-names>K.-C.</given-names></name>
</person-group><article-title>Highly potent antimicrobial modified peptides derived from the <italic toggle="yes">Acinetobacter baumannii</italic> phage endolysin LysAB2</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>11477</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-11832-7</pub-id><pub-id pub-id-type="pmid">28904355</pub-id>
</element-citation></ref><ref id="B39-viruses-17-00200"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Defraine</surname><given-names>V.</given-names></name>
<name><surname>Schuermans</surname><given-names>J.</given-names></name>
<name><surname>Grymonprez</surname><given-names>B.</given-names></name>
<name><surname>Govers</surname><given-names>S.K.</given-names></name>
<name><surname>Aertsen</surname><given-names>A.</given-names></name>
<name><surname>Fauvart</surname><given-names>M.</given-names></name>
<name><surname>Michiels</surname><given-names>J.</given-names></name>
<name><surname>Lavigne</surname><given-names>R.</given-names></name>
<name><surname>Briers</surname><given-names>Y.</given-names></name>
</person-group><article-title>Efficacy of Artilysin Art-175 against Resistant and Persistent <italic toggle="yes">Acinetobacter baumannii</italic></article-title><source>Antimicrob. Agents Chemother.</source><year>2016</year><volume>60</volume><fpage>3480</fpage><lpage>3488</lpage><pub-id pub-id-type="doi">10.1128/AAC.00285-16</pub-id><pub-id pub-id-type="pmid">27021321</pub-id>
</element-citation></ref><ref id="B40-viruses-17-00200"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>F.M.</given-names></name>
<name><surname>Gondil</surname><given-names>V.S.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Jiang</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>H.</given-names></name>
</person-group><article-title>A Novel <italic toggle="yes">Acinetobacter baumannii</italic> Bacteriophage Endolysin LysAB54 With High Antibacterial Activity Against Multiple Gram-Negative Microbes</article-title><source>Front. Cell. Infect. Microbiol.</source><year>2021</year><volume>11</volume><elocation-id>637313</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2021.637313</pub-id><pub-id pub-id-type="pmid">33738267</pub-id>
</element-citation></ref><ref id="B41-viruses-17-00200"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chu</surname><given-names>D.</given-names></name>
<name><surname>Lan</surname><given-names>J.</given-names></name>
<name><surname>Liang</surname><given-names>L.</given-names></name>
<name><surname>Xia</surname><given-names>K.</given-names></name>
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
</person-group><article-title>The antibacterial activity of a novel highly thermostable endolysin, LysKP213, against Gram-negative pathogens is enhanced when combined with outer membrane permeabilizing agents</article-title><source>Front. Microbiol.</source><year>2024</year><volume>15</volume><elocation-id>1454618</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2024.1454618</pub-id><pub-id pub-id-type="pmid">39439944</pub-id>
</element-citation></ref><ref id="B42-viruses-17-00200"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Huang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>X.</given-names></name>
</person-group><article-title>A novel endolysin from an <italic toggle="yes">Enterococcus faecalis</italic> phage and application</article-title><source>Microb. Pathog.</source><year>2024</year><volume>192</volume><fpage>106689</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2024.106689</pub-id><pub-id pub-id-type="pmid">38750777</pub-id>
</element-citation></ref><ref id="B43-viruses-17-00200"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Strange</surname><given-names>J.E.S.</given-names></name>
<name><surname>Leekitcharoenphon</surname><given-names>P.</given-names></name>
<name><surname>M&#x000f8;ller</surname><given-names>F.D.</given-names></name>
<name><surname>Aarestrup</surname><given-names>F.M.</given-names></name>
</person-group><article-title>Metagenomics analysis of bacteriophages and antimicrobial resistance from global urban sewage</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>1600</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-80990-6</pub-id><pub-id pub-id-type="pmid">33452346</pub-id>
</element-citation></ref><ref id="B44-viruses-17-00200"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Howell</surname><given-names>A.A.</given-names></name>
<name><surname>Versoza</surname><given-names>C.J.</given-names></name>
<name><surname>Pfeifer</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Computational host range prediction&#x02014;The good, the bad, and the ugly</article-title><source>Virus Evol.</source><year>2024</year><volume>10</volume><fpage>vead083</fpage><pub-id pub-id-type="doi">10.1093/ve/vead083</pub-id><pub-id pub-id-type="pmid">38361822</pub-id>
</element-citation></ref><ref id="B45-viruses-17-00200"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gerstmans</surname><given-names>H.</given-names></name>
<name><surname>Grimon</surname><given-names>D.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>D.</given-names></name>
<name><surname>Lood</surname><given-names>C.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name>
<name><surname>van Noort</surname><given-names>V.</given-names></name>
<name><surname>Lammertyn</surname><given-names>J.</given-names></name>
<name><surname>Lavigne</surname><given-names>R.</given-names></name>
<name><surname>Briers</surname><given-names>Y.</given-names></name>
</person-group><article-title>A VersaTile-driven platform for rapid hit-to-lead development of engineered lysins</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaaz1136</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaz1136</pub-id><pub-id pub-id-type="pmid">32537492</pub-id>
</element-citation></ref><ref id="B46-viruses-17-00200"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>E.M.</given-names></name>
<name><surname>Sychantha</surname><given-names>D.</given-names></name>
<name><surname>Brewer</surname><given-names>D.</given-names></name>
<name><surname>Clarke</surname><given-names>A.J.</given-names></name>
<name><surname>Geddes-McAlister</surname><given-names>J.</given-names></name>
<name><surname>Khursigara</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Peptidoglycomics reveals compositional changes in peptidoglycan between biofilm- and planktonic-derived Pseudomonas aeruginosa</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>504</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.010505</pub-id><pub-id pub-id-type="pmid">31771981</pub-id>
</element-citation></ref><ref id="B47-viruses-17-00200"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gantz</surname><given-names>M.</given-names></name>
<name><surname>Aleku</surname><given-names>G.A.</given-names></name>
<name><surname>Hollfelder</surname><given-names>F.</given-names></name>
</person-group><article-title>Ultrahigh-throughput screening in microfluidic droplets: A faster route to new enzymes</article-title><source>Trends Biochem. Sci.</source><year>2022</year><volume>47</volume><fpage>451</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2021.11.001</pub-id><pub-id pub-id-type="pmid">34848125</pub-id>
</element-citation></ref><ref id="B48-viruses-17-00200"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van Kempen</surname><given-names>M.</given-names></name>
<name><surname>Kim</surname><given-names>S.S.</given-names></name>
<name><surname>Tumescheit</surname><given-names>C.</given-names></name>
<name><surname>Mirdita</surname><given-names>M.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Gilchrist</surname><given-names>C.L.M.</given-names></name>
<name><surname>S&#x000f6;ding</surname><given-names>J.</given-names></name>
<name><surname>Steinegger</surname><given-names>M.</given-names></name>
</person-group><article-title>Fast and accurate protein structure search with Foldseek</article-title><source>Nat. Biotechnol.</source><year>2023</year><volume>42</volume><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01773-0</pub-id><pub-id pub-id-type="pmid">37156916</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-00200-f001"><label>Figure 1</label><caption><p>Discovery of natural endolysins against <italic toggle="yes">A. baumannii.</italic> (<bold>A</bold>) Workflow for the identification of endolysin against <italic toggle="yes">A. baumannii</italic>. (<bold>B</bold>) Representative image (left) and summary (right) of plate lysis assay using a lysate of recombinant expressing endolysins. The bar represents the area where the turbidity of the agar plate decreased. Error bars were only displayed for genes evaluated by lysates from multiple clones. The numbers above each bar exhibit identity (%) toward top hit endolysin in PhaLP.</p></caption><graphic xlink:href="viruses-17-00200-g001" position="float"/></fig><fig position="float" id="viruses-17-00200-f002"><label>Figure 2</label><caption><p>Discovery of chimera AMP&#x02013;endolysins inhibiting the growth of <italic toggle="yes">A. baumannii.</italic> (<bold>A</bold>) Workflow for the generation of chimeric endolysin inhibiting growth of <italic toggle="yes">A. baumannii</italic>. One endolysin and one AMP are randomly conjugated and recombined into the expression vector by Gibson assembly. (<bold>B</bold>) Growth inhibitory assay against <italic toggle="yes">A. baumannii</italic>. The normalized growth of <italic toggle="yes">A. baumannii</italic> treated by chimeric endolysin in the lysate was calculated from the absorbance of bacterial culture after 16 h incubation. The absorbance of culture treated by lysate of the empty vector recombinant was used as the standard value.</p></caption><graphic xlink:href="viruses-17-00200-g002" position="float"/></fig><fig position="float" id="viruses-17-00200-f003"><label>Figure 3</label><caption><p>MIC assay of chimera AMP&#x02013;endolysins. Bar plot showed relative growth of <italic toggle="yes">A. baumannii</italic> treated by chimeric endolysin (<bold>A</bold>) bbgn0031, (<bold>B</bold>) bbgn0033, (<bold>C</bold>) bbgn0043, and (<bold>D</bold>) bbgn0044. The relative growth was calculated from the absorbance of culture. The absorbance of culture which was not treated with endolysin was used as the standard value. Significance was analyzed by the Tukey&#x02013;Kramer test based on one-way ANOVA and is indicated by asterisks compared to growth of the untreated bacteria (*: <italic toggle="yes">p</italic> &#x0003c; 0.05, **: <italic toggle="yes">p</italic> &#x0003c; 0.01). The image below the graph shows a visual observation of the culture.</p></caption><graphic xlink:href="viruses-17-00200-g003" position="float"/></fig><fig position="float" id="viruses-17-00200-f004"><label>Figure 4</label><caption><p>Cytotoxicity assay and biofilm-degrading assay of chimera AMP&#x02013;endolysins. (<bold>A</bold>) Cytotoxicity assay of chimera AMP&#x02013;endolysins. The cytotoxicity effect of endolysins was evaluated with the Caco-2 cell line. Relative cell viability was calculated from the absorbance acquired by the CCK-8 assay. The absorbance of the culture treated with PBS was used as the standard value. (<bold>B</bold>) Biofilm-degrading assay of chimera AMP&#x02013;endolysins with <italic toggle="yes">P. aeruginosa</italic> biofilm. Lower absorbance indicates stronger degradation activity. Both assays were performed with triplicate samples. Significance was analyzed by the Tukey&#x02013;Kramer test based on one-way ANOVA and is indicated by asterisks compared to the PBS-treated samples (**: <italic toggle="yes">p</italic> &#x0003c; 0.01).</p></caption><graphic xlink:href="viruses-17-00200-g004" position="float"/></fig><table-wrap position="float" id="viruses-17-00200-t001"><object-id pub-id-type="pii">viruses-17-00200-t001_Table 1</object-id><label>Table 1</label><caption><p>Antimicrobial spectra of chimera AMP&#x02013;endolysins.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td rowspan="3" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Tested Bacteria</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">bbgn0031</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">bbgn0033</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">bbgn0043</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">bbgn0044</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">* chmrAMP</td><td align="center" valign="middle" rowspan="1" colspan="1">* P81417</td><td align="center" valign="middle" rowspan="1" colspan="1">* Q963A8</td><td align="center" valign="middle" rowspan="1" colspan="1">* Q963A8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** SGM003-00043_05170</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** SGM003-00043_05170</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** SGM003-00043_05170</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** SGM007-00005_02751</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gram-positive</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Staphylococcus aureus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Streptococcus gallolyticus</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Bacillus subtilis</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Enterococcus faecalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Gram-negative</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Escherichia coli</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Acinetobacter baumannii</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pseudomonas aeruginosa</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Enterobacter cloacae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella aerogenes</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Klebsiella pneumoniae</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;32</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">Fusobacterium nucleatum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;32</td></tr></tbody></table><table-wrap-foot><fn><p>The values represent MIC (&#x000b5;g/mL) for tested bacterial species. * AMP, ** natural endolysin.</p></fn></table-wrap-foot></table-wrap></floats-group></article>